Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy

Laura Boyero, Amparo Sánchez-Gastaldo, Miriam Alonso, José Francisco Noguera-Uclés, Sonia Molina-Pinelo, Reyes Bernabé-Caro, Laura Boyero, Amparo Sánchez-Gastaldo, Miriam Alonso, José Francisco Noguera-Uclés, Sonia Molina-Pinelo, Reyes Bernabé-Caro

Abstract

After several decades without maintained responses or long-term survival of patients with lung cancer, novel therapies have emerged as a hopeful milestone in this research field. The appearance of immunotherapy, especially immune checkpoint inhibitors, has improved both the overall survival and quality of life of patients, many of whom are diagnosed late when classical treatments are ineffective. Despite these unprecedented results, a high percentage of patients do not respond initially to treatment or relapse after a period of response. This is due to resistance mechanisms, which require understanding in order to prevent them and develop strategies to overcome them and increase the number of patients who can benefit from immunotherapy. This review highlights the current knowledge of the mechanisms and their involvement in resistance to immunotherapy in lung cancer, such as aberrations in tumor neoantigen burden, effector T-cell infiltration in the tumor microenvironment (TME), epigenetic modulation, the transcriptional signature, signaling pathways, T-cell exhaustion, and the microbiome. Further research dissecting intratumor and host heterogeneity is necessary to provide answers regarding the immunotherapy response and develop more effective treatments for lung cancer.

Keywords: NSCLC; PD-1/PD-L1; SCLC; immune checkpoint inhibitors; immunotherapy; lung cancer; monoclonal antibodies; resistance mechanisms.

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Figures

Figure 1
Figure 1
Different strategies and immunotherapeutic agents with clinical application in lung cancer. Created with Biorander.com.
Figure 2
Figure 2
Classification of the most relevant resistance mechanisms to ICI therapies operating in lung cancer.

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492.
    1. De Groot P.M., Wu C.C., Carter B.W., Munden R.F. The epidemiology of lung cancer. Transl. Lung Cancer Res. 2018;7:220–233. doi: 10.21037/tlcr.2018.05.06.
    1. Global Cancer Observatory. [(accessed on 11 March 2020)]; Available online:
    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. CA Cancer J. Clin. 2020;70:7–30. doi: 10.3322/caac.21590.
    1. Barta J.A., Powell C.A., Wisnivesky J.P. Global epidemiology of lung cancer. Ann. Glob. Health. 2019;85:8. doi: 10.5334/aogh.2419.
    1. Gabrielson E. Worldwide trends in lung cancer pathology. Respirology. 2006;11:533–538. doi: 10.1111/j.1440-1843.2006.00909.x.
    1. Perera F.P., Mooney L.A., Stampfer M., Phillips D.H., Bell D.A., Rundle A., Cho S., Tsai W.-Y., Ma J., Blackwood A., et al. Associations between carcinogen-DNA damage, glutathione S-transferase genotypes, and risk of lung cancer in the prospective Physicians’ Health Cohort Study. Carcinogenesis. 2002;23:1641–1646. doi: 10.1093/carcin/23.10.1641.
    1. Tang D., Phillips D.H., Stampfer M., Mooney L.A., Hsu Y., Cho S., Tsai W.Y., Ma J., Cole K.J., Shé M.N., et al. Association between carcinogen-DNA adducts in white blood cells and lung cancer risk in the physicians health study. Cancer Res. 2001;61:6708–6712.
    1. Govindan R., Ding L., Griffith M., Subramanian J., Dees N.D., Kanchi K.L., Maher C.A., Fulton R., Fulton L., Wallis J., et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 2012;150:1121–1134. doi: 10.1016/j.cell.2012.08.024.
    1. Pesch B., Kendzia B., Gustavsson P., Jöckel K.H., Johnen G., Pohlabeln H., Olsson A., Ahrens W., Gross I.M., Brüske I., et al. Cigarette smoking and lung cancer—Relative risk estimates for the major histological types from a pooled analysis of case—Control studies. Int. J. Cancer. 2012;131:1210–1219. doi: 10.1002/ijc.27339.
    1. Travis W.D., Brambilla E., Nicholson A.G., Yatabe Y., Austin J.H.M., Beasley M.B., Chirieac L.R., Dacic S., Duhig E., Flieder D.B., et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances since the 2004 Classification. J. Thorac. Oncol. 2015;10:1243–1260. doi: 10.1097/JTO.0000000000000630.
    1. Postmus P.E., Kerr K.M., Oudkerk M., Senan S., Waller D.A., Vansteenkiste J., Escriu C., Peters S., ESMO Guidelines Committee Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2017;28:iv1–iv21. doi: 10.1093/annonc/mdx222.
    1. Li Z., Yu Y., Lu J., Luo Q., Wu C., Liao M., Zheng Y., Ai X., Gu L., Lu S. Analysis of the T descriptors and other prognosis factors in pathologic stage I non-small cell lung cancer in China. J. Thorac. Oncol. 2009;4:702–709. doi: 10.1097/JTO.0b013e3181a5269d.
    1. Eberhardt W.E.E., De Ruysscher D., Weder W., Le Péchoux C., De Leyn P., Hoffmann H., Westeel V., Stahel R., Felip E., Peters S., et al. 2nd ESMO Consensus Conference in Lung Cancer: Locally advanced stage III non-small-cell lung cancer. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2015;26:1573–1588. doi: 10.1093/annonc/mdv187.
    1. Uramoto H., Tanaka F. Recurrence after surgery in patients with NSCLC. Transl. Lung Cancer Res. 2014;3:242–249. doi: 10.3978/j.issn.2218-6751.2013.12.05.
    1. Planchard D., Popat S., Kerr K., Novello S., Smit E.F., Faivre-Finn C., Mok T.S., Reck M., Van Schil P.E., Hellmann M.D., et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2018;29(Suppl. 4):iv192–iv237. doi: 10.1093/annonc/mdy275.
    1. Stewart L.A., Pignon J.P. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br. Med. J. 1995;311:899–909. doi: 10.1016/0169-5002(96)85918-6.
    1. Amini A., Yeh N., Gaspar L.E., Kavanagh B., Karam S.D. Stereotactic body radiation therapy (SBRT) for lung cancer patients previously treated with conventional radiotherapy: A review. Radiat. Oncol. 2014;9:210. doi: 10.1186/1748-717X-9-210.
    1. Ramalingam S., Belani C. Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions. Oncologist. 2008;13:5–13. doi: 10.1634/theoncologist.13-S1-5.
    1. Zugazagoitia J., Molina-Pinelo S., Lopez-Rios F., Paz-Ares L. Biological therapies in non small cell lung cancer. Eur. Respir. J. 2017;49 doi: 10.1183/13993003.01520-2016.
    1. Schrank Z., Chhabra G., Lin L., Iderzorig T., Osude C., Khan N., Kuckovic A., Singh S., Miller R.J., Puri N. Current molecular-targeted therapies in NSCLC and their mechanism of resistance. Cancers. 2018;10:224. doi: 10.3390/cancers10070224.
    1. Liu W.J., Du Y., Wen R., Yang M., Xu J. Drug resistance to targeted therapeutic strategies in non-small cell lung cancer. Pharmacol. Ther. 2020;206:107438. doi: 10.1016/j.pharmthera.2019.107438.
    1. Rotow J., Bivona T.G. Understanding and targeting resistance mechanisms in NSCLC. Nat. Rev. Cancer. 2017;17:637–658. doi: 10.1038/nrc.2017.84.
    1. Gandara D.R., Hammerman P.S., Sos M.L., Lara P.N., Hirsch F.R. Squamous cell lung cancer: From tumor genomics to cancer therapeutics. Clin. Cancer Res. 2015;21:2236–2243. doi: 10.1158/1078-0432.CCR-14-3039.
    1. Shalapour S., Karin M. Immunity, inflammation, and cancer: An eternal fight between good and evil. J. Clin. Investig. 2015;125:3347–3355. doi: 10.1172/JCI80007.
    1. Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell. 2011;144:646–674. doi: 10.1016/j.cell.2011.02.013.
    1. Schuster M., Nechansky A., Loibner H., Kircheis R. Cancer immunotherapy. Biotechnol. J. 2006;1:138–147. doi: 10.1002/biot.200500044.
    1. Michaelidou K., Agelaki S., Mavridis K. Molecular markers related to immunosurveillance as predictive and monitoring tools in non-small cell lung cancer: Recent accomplishments and future promises. Expert Rev. Mol. Diagn. 2020;20:335–344. doi: 10.1080/14737159.2020.1724785.
    1. Emens L.A., Ascierto P.A., Darcy P.K., Demaria S., Eggermont A.M.M., Redmond W.L., Seliger B., Marincola F.M. Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. Eur. J. Cancer. 2017;81:116–129. doi: 10.1016/j.ejca.2017.01.035.
    1. Farkona S., Diamandis E.P., Blasutig I.M. Cancer immunotherapy: The beginning of the end of cancer? BMC Med. 2016;14:1–18. doi: 10.1186/s12916-016-0623-5.
    1. Tran L., Theodorescu D. Determinants of resistance to checkpoint inhibitors. Int. J. Mol. Sci. 2020;21:1594. doi: 10.3390/ijms21051594.
    1. Monjazeb A.M., Hsiao H.-H., Sckisel G.D., Murphy W.J. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer. J. Immunotoxicol. 2012;9:248–258. doi: 10.3109/1547691X.2012.685527.
    1. Lichty B.D., Breitbach C.J., Stojdl D.F., Bell J.C. Going viral with cancer immunotherapy. Nat. Rev. Cancer. 2014;14:559–567. doi: 10.1038/nrc3770.
    1. Fukuhara H., Ino Y., Todo T. Oncolytic virus therapy: A new era of cancer treatment at dawn. Cancer Sci. 2016;107:1373–1379. doi: 10.1111/cas.13027.
    1. Raja J., Ludwig J.M., Gettinger S.N., Schalper K.A., Kim H.S. Oncolytic virus immunotherapy: Future prospects for oncology. J. Immunother. Cancer. 2018;6:140. doi: 10.1186/s40425-018-0458-z.
    1. Goldufsky J., Sivendran S., Harcharik S., Pan M., Bernardo S., Stern R.H., Friedlander P., Ruby C., Saenger Y., Kaufman H. Oncolytic virus therapy for cancer. Oncolytic Virother. 2013;2:31. doi: 10.2147/ov.s38901.
    1. Saab S., Zalzale H., Rahal Z., Khalifeh Y., Sinjab A., Kadara H. Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment. Front. Immunol. 2020;11:159. doi: 10.3389/fimmu.2020.00159.
    1. Quoix E., Lena H., Losonczy G., Forget F., Chouaid C., Papai Z., Gervais R., Ottensmeier C., Szczesna A., Kazarnowicz A., et al. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): Results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. Lancet Oncol. 2016;17:212–223. doi: 10.1016/S1470-2045(15)00483-0.
    1. Remy-Ziller C., Thioudellet C., Hortelano J., Gantzer M., Nourtier V., Claudepierre M.C., Sansas B., Préville X., Bendjama K., Quemeneur E., et al. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model. Hum. Vaccines Immunother. 2018;14:140–145. doi: 10.1080/21645515.2017.1373921.
    1. Peters C., Grandi P., Nigim F. Updates on Oncolytic Virus Immunotherapy for Cancers. Mol. Ther. Oncolytics. 2019;12:259–262. doi: 10.1016/j.omto.2019.01.008.
    1. Phase Ib KEYNOTE-200: A Study of an Intravenously Delivered Oncolytic Virus, Coxsackievirus A21 in Combination with Pembrolizumab in Advanced NSCLC and Bladder Cancer Patients—Annals of Oncology. [(accessed on 13 May 2020)]; Available online: .
    1. Deng H., Liu H., de Silva T., Xue Y.C., Mohamud Y., Ng C.S., Qu J., Zhang J., Jia W.W.G., Lockwood W.W., et al. Coxsackievirus Type B3 Is a Potent Oncolytic Virus against KRAS-Mutant Lung Adenocarcinoma. Mol. Ther. Oncolytics. 2019;14:266–278. doi: 10.1016/j.omto.2019.07.003.
    1. Atasheva S., Yao J., Young C., Paolo N.C.D., Wyche H., Shayakhmetov D.M. Abstract 4781: Preclinical assessment of efficacy and safety of novel oncolytic adenovirus for therapy of disseminated lung cancer. Cancer Res. 2019;79:4781. doi: 10.1158/1538-7445.AM2019-4781.
    1. Patel M.R., Jacobson B.A., Belgum H., Raza A., Sadiq A., Drees J., Wang H., Jay-Dixon J., Etchison R., Federspiel M.J., et al. Measles vaccine strains for virotherapy of non-small-cell lung carcinoma. J. Thorac. Oncol. 2014;9:1101–1110. doi: 10.1097/JTO.0000000000000214.
    1. Kellish P., Shabashvili D., Rahman M.M., Nawab A., Guijarro M.V., Zhang M., Cao C., Moussatche N., Boyle T., Antonia S., et al. Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival. J. Clin. Investig. 2019;129:2279–2292. doi: 10.1172/JCI121323.
    1. Oliveres H., Caglevic C., Passiglia F., Taverna S., Smits E., Rolfo C. Vaccine and immune cell therapy in non-small cell lung cancer. J. Thorac. Dis. 2018;10:S1602–S1614. doi: 10.21037/jtd.2018.05.134.
    1. Sanghera C., Sanghera R. Immunotherapy—Strategies for Expanding Its Role in the Treatment of All Major Tumor Sites. Cureus. 2019;11:e5938. doi: 10.7759/cureus.5938.
    1. Perica K., Varela J.C., Oelke M., Schneck J. Adoptive T Cell Immunotherapy for Cancer. Rambam Maimonides Med. J. 2015;6:e0004. doi: 10.5041/RMMJ.10179.
    1. Cho J.H., Collins J.J., Wong W.W. Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses. Cell. 2018;173:1426–1438.e11. doi: 10.1016/j.cell.2018.03.038.
    1. Finn O.J. Molecular origins of cancer: Cancer immunology. N. Engl. J. Med. 2008;358:2704–2715. doi: 10.1056/NEJMra072739.
    1. Kimiz-Gebologlu I., Gulce-Iz S., Biray-Avci C. Monoclonal antibodies in cancer immunotherapy. Mol. Biol. Rep. 2018;45:2935–2940. doi: 10.1007/s11033-018-4427-x.
    1. Tagliamento M., Rijavec E., Barletta G., Biello F., Rossi G., Grossi F., Genova C. CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine. Expert Opin. Biol. Ther. 2018;18:829–835. doi: 10.1080/14712598.2018.1492539.
    1. Gabri M.R., Cacciavillano W., Chantada G.L., Alonso D.F. Racotumomab for treating lung cancer and pediatric refractory malignancies. Expert Opin. Biol. Ther. 2016;16:573–578. doi: 10.1517/14712598.2016.1157579.
    1. Alfonso S., Valdés-Zayas A., Santiesteban E.R., Flores Y.I., Areces F., Hernández M., Viada C.E., Mendoza I.C., Guerra P.P., García E., et al. A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin. Cancer Res. 2014;20:3660–3671. doi: 10.1158/1078-0432.CCR-13-1674.
    1. Weiner L.M., Surana R., Wang S. Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 2010;10:317–327. doi: 10.1038/nri2744.
    1. Mayrhofer P., Kunert R. Nomenclature of humanized mAbs: Early concepts, current challenges and future perspectives. Hum. Antibodies. 2018;27:37–51. doi: 10.3233/HAB-180347.
    1. Silva A.P.S., Coelho P.V., Anazetti M., Simioni P.U. Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors. Hum. Vaccines Immunother. 2017;13:843–853. doi: 10.1080/21645515.2016.1249551.
    1. Regzedmaa O., Zhang H., Liu H., Chen J. Immune checkpoint inhibitors for small cell lung cancer: Opportunities and challenges. OncoTargets. Ther. 2019;12:4605–4620. doi: 10.2147/OTT.S204577.
    1. Berghmans T., Durieux V., Hendriks L.E.L., Dingemans A.-M. Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept. Front. Med. 2020;7:90. doi: 10.3389/fmed.2020.00090.
    1. Gettinger S., Horn L., Jackman D., Spigel D., Antonia S., Hellmann M., Powderly J., Heist R., Sequist L.V., Smith D.C., et al. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. J. Clin. Oncol. 2018;36:1675–1684. doi: 10.1200/JCO.2017.77.0412.
    1. Rolfo C., Caglevic C., Santarpia M., Araujo A., Giovannetti E., Gallardo C.D., Pauwels P., Mahave M. Immunotherapy in NSCLC: A promising and revolutionary weapon. Adv. Exp. Med. Biol. 2017;995:97–125. doi: 10.1007/978-3-319-53156-4_5.
    1. Horn L., Spigel D.R., Vokes E.E., Holgado E., Ready N., Steins M., Poddubskaya E., Borghaei H., Felip E., Paz-Ares L., et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: Two-year outcomes from two randomized, open-label, phase III Trials (CheckMate 017 and CheckMate 057) J. Clin. Oncol. 2017;35:3924–3933. doi: 10.1200/JCO.2017.74.3062.
    1. Yan Y., Zheng Y., Ming P., Deng X., Ge W., Wu Y. Immune checkpoint inhibitors in non-small-cell lung cancer: Current status and future directions. Brief. Funct. Genom. 2018;18:147–156. doi: 10.1093/bfgp/ely029.
    1. Herbst R.S., Baas P., Kim D.W., Felip E., Pérez-Gracia J.L., Han J.Y., Molina J., Kim J.H., Arvis C.D., Ahn M.J., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet. 2016;387:1540–1550. doi: 10.1016/S0140-6736(15)01281-7.
    1. Cortinovis D., Gadgeel S.M., Rittmeyer A., Barlesi F., Cobo Dols M., Hida T., He P., Ballinger M., Gandara D.R., von Pawel J. Results from OAK subgroup analyses: A randomized Phase III study of atezolizumab vs. docetaxel in patients (pts) with advanced NSCLC. Ann. Oncol. 2017;28:II32. doi: 10.1093/annonc/mdx091.009.
    1. Rittmeyer A., Barlesi F., Waterkamp D., Park K., Ciardiello F., von Pawel J., Gadgeel S.M., Hida T., Kowalski D.M., Dols M.C., et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255–265. doi: 10.1016/S0140-6736(16)32517-X.
    1. Reck M., Rodriguez-Abreu D., Robinson A.G., Hui R., Csöszi T., Fülöp A., Gottfried M., Peled N., Tafreshi A., Cuffe S., et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2016;375:1823–1833. doi: 10.1056/NEJMoa1606774.
    1. Gandhi L., Rodríguez-Abreu D., Gadgeel S., Esteban E., Felip E., De Angelis F., Domine M., Clingan P., Hochmair M.J., Powell S.F., et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 2018;378:2078–2092. doi: 10.1056/NEJMoa1801005.
    1. Reck M., Mok T.S.K., Nishio M., Jotte R.M., Cappuzzo F., Orlandi F., Stroyakovskiy D., Nogami N., Rodríguez-Abreu D., Moro-Sibilot D., et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): Key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir. Med. 2019;7:387–401. doi: 10.1016/S2213-2600(19)30084-0.
    1. Hellmann M.D., Paz-Ares L., Bernabe Caro R., Zurawski B., Kim S.-W., Carcereny Costa E., Park K., Alexandru A., Lupinacci L., de la Mora Jimenez E., et al. Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2019;381:2020–2031. doi: 10.1056/NEJMoa1910231.
    1. Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J.J., Cowey C.L., Lao C.D., Schadendorf D., Dummer R., Smylie M., Rutkowski P., et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med. 2015;373:23–34. doi: 10.1056/NEJMoa1504030.
    1. Ramalingam S.S., Ciuleanu T.E., Pluzanski A., Lee J.-S., Schenker M., Bernabe Caro R., Lee K.H., Zurawski B., Audigier-Valette C., Provencio M., et al. Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1. J. Clin. Oncol. 2020;38:9500. doi: 10.1200/JCO.2020.38.15_suppl.9500.
    1. Hall E.T., Singhal S., Dickerson J., Gabster B., Wong H.N., Aslakson R.A., Schapira L., Aslakson R., Ast K., Carroll T., et al. Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care—A Systematic Review. J. Pain Symptom Manag. 2019;58:137–156.e1. doi: 10.1016/j.jpainsymman.2019.03.015.
    1. Tsiouprou I., Zaharias A., Spyratos D. The Role of Immunotherapy in Extensive Stage Small-Cell Lung Cancer: A Review of the Literature. Can. Respir. J. 2019;2019 doi: 10.1155/2019/6860432.
    1. Reck M., Ciuleanu T.-E., Dols M.C., Schenker M., Zurawski B., Menezes J., Richardet E., Bennouna J., Felip E., Juan-Vidal O., et al. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. J. Clin. Oncol. 2020;38:9501. doi: 10.1200/JCO.2020.38.15_suppl.9501.
    1. Yang H., Jin T., Li M., Xue J., Lu B. Synergistic effect of immunotherapy and radiotherapy in non-small cell lung cancer: Current clinical trials and prospective challenges. Precis. Clin. Med. 2019;2:57–70. doi: 10.1093/pcmedi/pbz004.
    1. Zhou J., Huang Q., Huang Z., Li J. Combining immunotherapy and radiotherapy in lung cancer: A promising future? J. Thorac. Dis. 2020;12:4498–4503. doi: 10.21037/JTD-2019-ITM-001.
    1. Rangel-Sosa M.M., Aguilar-Córdova E., Rojas-Martínez A. Immunotherapy and gene therapy as novel treatments for cancer. Colomb. Med. 2017;48:138–147. doi: 10.25100/cm.v48i3.2997.
    1. Zitvogel L., Pitt J.M., Daillère R., Smyth M.J., Kroemer G. Mouse models in oncoimmunology. Nat. Rev. Cancer. 2016;16:759–773. doi: 10.1038/nrc.2016.91.
    1. Sharma P., Hu-Lieskovan S., Wargo J.A., Ribas A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017;168:707–723. doi: 10.1016/j.cell.2017.01.017.
    1. Walsh R.J., Soo R.A. Resistance to immune checkpoint inhibitors in non-small cell lung cancer: Biomarkers and therapeutic strategies. Ther. Adv. Med. Oncol. 2020;12 doi: 10.1177/1758835920937902.
    1. Ribas A., Hamid O., Daud A., Hodi F.S., Wolchok J.D., Kefford R., Joshua A.M., Patnaik A., Hwu W.J., Weber J.S., et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315:1600–1609. doi: 10.1001/jama.2016.4059.
    1. McGray A.J.R., Bramson J. Adaptive resistance to cancer immunotherapy. Adv. Exp. Med. Biol. 2017;1036:213–227. doi: 10.1007/978-3-319-67577-0_14.
    1. Wang Q., Wu X. Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment. Int. Immunopharmacol. 2017;46:210–219. doi: 10.1016/j.intimp.2017.03.015.
    1. Jenkins R.W., Barbie D.A., Flaherty K.T. Mechanisms of resistance to immune checkpoint inhibitors. Br. J. Cancer. 2018;118:9–16. doi: 10.1038/bjc.2017.434.
    1. Shim J.H.H., Kim H.S.S., Cha H., Kim S., Kim T.M.M., Anagnostou V., Choi Y.-L.Y.-L., Jung H.A.A., Sun J.-M.J.-M.J.-M., Ahn J.S.S., et al. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients. Ann. Oncol. 2020;31:902–911. doi: 10.1016/j.annonc.2020.04.004.
    1. Fuereder T. Resistance to immune checkpoint inhibitors. Next steps and combinational approaches. Memo Mag. Eur. Med. Oncol. 2019;12:123–127. doi: 10.1007/s12254-019-0493-6.
    1. Syn N.L., Teng M.W.L., Mok T.S.K., Soo R.A. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol. 2017;18:e731–e741. doi: 10.1016/S1470-2045(17)30607-1.
    1. Rizvi N.A., Hellmann M.D., Snyder A., Kvistborg P., Makarov V., Havel J.J., Lee W., Yuan J., Wong P., Ho T.S., et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124–128. doi: 10.1126/science.aaa1348.
    1. Hellmann M.D., Nathanson T., Rizvi H., Creelan B.C., Sanchez-Vega F., Ahuja A., Ni A., Novik J.B., Mangarin L.M.B., Abu-Akeel M., et al. Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell. 2018;33:843–852.e4. doi: 10.1016/j.ccell.2018.03.018.
    1. Hellmann M.D., Callahan M.K., Awad M.M., Calvo E., Ascierto P.A., Atmaca A., Rizvi N.A., Hirsch F.R., Selvaggi G., Szustakowski J.D., et al. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell. 2018;33:853–861.e4. doi: 10.1016/j.ccell.2018.04.001.
    1. Park S., Lee H., Lee B., Lee S.H., Sun J.M., Park W.Y., Ahn J.S., Ahn M.J., Park K. DNA Damage Response and Repair Pathway Alteration and Its Association with Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC. J. Thorac. Oncol. 2019;14:1640–1650. doi: 10.1016/j.jtho.2019.05.014.
    1. Alexandrov L.B., Nik-Zainal S., Wedge D.C., Aparicio S.A.J.R., Behjati S., Biankin A.V., Bignell G.R., Bolli N., Borg A., Børresen-Dale A.L., et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–421. doi: 10.1038/nature12477.
    1. Galuppini F., Dal Pozzo C.A., Deckert J., Loupakis F., Fassan M., Baffa R. Tumor mutation burden: From comprehensive mutational screening to the clinic. Cancer Cell Int. 2019;19:1–10. doi: 10.1186/s12935-019-0929-4.
    1. Le D.T., Durham J.N., Smith K.N., Wang H., Bartlett B.R., Aulakh L.K., Lu S., Kemberling H., Wilt C., Luber B.S., et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409–413. doi: 10.1126/science.aan6733.
    1. Shergold A.L., Millar R., Nibbs R.J.B. Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade. Pharmacol. Res. 2019;145:104258. doi: 10.1016/j.phrs.2019.104258.
    1. Carbone D.P., Reck M., Paz-Ares L., Creelan B., Horn L., Steins M., Felip E., Van Den Heuvel M.M., Ciuleanu T.E., Badin F., et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N. Engl. J. Med. 2017;376:2415–2426. doi: 10.1056/NEJMoa1613493.
    1. Hellmann M.D., Ciuleanu T.E., Pluzanski A., Lee J.S., Otterson G.A., Audigier-Valette C., Minenza E., Linardou H., Burgers S., Salman P., et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 2018;378:2093–2104. doi: 10.1056/NEJMoa1801946.
    1. McGranahan N., Furness A.J.S., Rosenthal R., Ramskov S., Lyngaa R., Saini S.K., Jamal-Hanjani M., Wilson G.A., Birkbak N.J., Hiley C.T., et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463–1469. doi: 10.1126/science.aaf1490.
    1. Rosenthal R., Cadieux E.L., Salgado R., Bakir M.A., Moore D.A., Hiley C.T., Lund T., Tanić M., Reading J.L., Joshi K., et al. Neoantigen-directed immune escape in lung cancer evolution. Nature. 2019;567:479–485. doi: 10.1038/s41586-019-1032-7.
    1. Geng Y., Shao Y., He W., Hu W., Xu Y., Chen J., Wu C., Jiang J. Prognostic role of tumor-infiltrating lymphocytes in lung cancer: A meta-analysis. Cell. Physiol. Biochem. 2015;37:1560–1571. doi: 10.1159/000438523.
    1. Neeve S.C., Robinson B.W.S., Fear V.S. The role and therapeutic implications of T cells in cancer of the lung. Clin. Transl. Immunol. 2019;8:e1076. doi: 10.1002/cti2.1076.
    1. Goc J., Germain C., Vo-Bourgais T.K.D., Lupo A., Klein C., Knockaert S., De Chaisemartin L., Ouakrim H., Becht E., Alifano M., et al. Dendritic cells in tumor-associated tertiary lymphoid structures signal a th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ t cells. Cancer Res. 2014;74:705–715. doi: 10.1158/0008-5472.CAN-13-1342.
    1. Wang S., Wang Z. Efficacy and safety of dendritic cells co-cultured with cytokine-induced killer cells immunotherapy for non-small-cell lung cancer. Int. Immunopharmacol. 2015;28:22–28. doi: 10.1016/j.intimp.2015.05.021.
    1. Garris C.S., Arlauckas S.P., Kohler R.H., Trefny M.P., Garren S., Piot C., Engblom C., Pfirschke C., Siwicki M., Gungabeesoon J., et al. Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12. Immunity. 2018;49:1148–1161.e7. doi: 10.1016/j.immuni.2018.09.024.
    1. Lakins M.A., Ghorani E., Munir H., Martins C.P., Shields J.D. Cancer-associated fibroblasts induce antigen-specific deletion of CD8 + T Cells to protect tumour cells. Nat. Commun. 2018;9:1–9. doi: 10.1038/s41467-018-03347-0.
    1. Villanueva L., Álvarez-Errico D., Esteller M. The Contribution of Epigenetics to Cancer Immunotherapy. Trends Immunol. 2020;41:676–691. doi: 10.1016/j.it.2020.06.002.
    1. Wachowska M., Gabrysiak M., Golab J. Epigenetic remodeling combined with photodynamic therapy elicits anticancer immune responses. Oncoimmunology. 2014;3:e28837. doi: 10.4161/onci.28837.
    1. Chen X., Pan X., Zhang W., Guo H., Cheng S., He Q., Yang B., Ding L. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses. Acta Pharm. Sin. B. 2020;10:723–733. doi: 10.1016/j.apsb.2019.09.006.
    1. Peixoto P., Renaude E., Boyer-Guittaut M., Hervouet E. Epigenetics, a key player of immunotherapy resistance. Cancer Drug Resist. 2018;1:219–229. doi: 10.20517/cdr.2018.17.
    1. Marwitz S., Scheufele S., Perner S., Reck M., Ammerpohl O., Goldmann T. Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression. Clin. Epigenetics. 2017;9:1–3. doi: 10.1186/s13148-017-0354-2.
    1. Zhang Y., Xiang C., Wang Y., Duan Y., Liu C., Zhang Y. PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance. Oncotarget. 2017;8:101535–101544. doi: 10.18632/oncotarget.21328.
    1. Asgarova A., Asgarov K., Godet Y., Peixoto P., Nadaradjane A., Boyer-Guittaut M., Galaine J., Guenat D., Mougey V., Perrard J., et al. PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma. Oncoimmunology. 2018;7:e1423170. doi: 10.1080/2162402X.2017.1423170.
    1. Duruisseaux M., Martínez-Cardús A., Calleja-Cervantes M.E., Moran S., Castro de Moura M., Davalos V., Piñeyro D., Sanchez-Cespedes M., Girard N., Brevet M., et al. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: A multicentre, retrospective analysis. Lancet Respir. Med. 2018;6:771–781. doi: 10.1016/S2213-2600(18)30284-4.
    1. Rodriguez-Pascual J., Ayuso-Sacido A., Belda-Iniesta C. Drug resistance in cancer immunotherapy: New strategies to improve checkpoint inhibitor therapies. Cancer Drug Resist. 2019;2:980–993. doi: 10.20517/cdr.2019.61.
    1. Hugo W., Zaretsky J.M., Sun L., Song C., Moreno B.H., Hu-Lieskovan S., Berent-Maoz B., Pang J., Chmielowski B., Cherry G., et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell. 2016;165:35–44. doi: 10.1016/j.cell.2016.02.065.
    1. Kim T.K., Herbst R.S., Chen L. Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol. 2018;39:624–631. doi: 10.1016/j.it.2018.05.001.
    1. Gainor J.F., Shaw A.T., Sequist L.V., Fu X., Azzoli C.G., Piotrowska Z., Huynh T.G., Zhao L., Fulton L., Schultz K.R., et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: A retrospective analysis. Clin. Cancer Res. 2016;22:4585–4593. doi: 10.1158/1078-0432.CCR-15-3101.
    1. Teng M.W.L., Ngiow S.F., Ribas A., Smyth M.J. Classifying cancers basedon T-cell infiltration and PD-L1. Cancer Res. 2015;75:2139–2145. doi: 10.1158/0008-5472.CAN-15-0255.
    1. Zhang Y., Chen L. Classification of advanced human cancers based on tumor immunity in the MicroEnvironment (TIME) for cancer immunotherapy. JAMA Oncol. 2016;2:1403–1404. doi: 10.1001/jamaoncol.2016.2450.
    1. Hamada T., Soong T.R., Masugi Y., Kosumi K., Nowak J.A., da Silva A., Mu X.J., Twombly T.S., Koh H., Yang J., et al. TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas. Oncoimmunology. 2018;7:e1442999. doi: 10.1080/2162402X.2018.1442999.
    1. Hao J., Wang H., Song L., Li S., Che N., Zhang S., Zhang H., Wang J. Infiltration of CD8+ FOXP3+ T cells, CD8+ T cells, and FOXP3+ T cells in non-small cell lung cancer microenvironment. Int. J. Clin. Exp. Pathol. 2020;13:880–888.
    1. Zhang Z., Liu S., Zhang B., Qiao L., Zhang Y., Zhang Y. T Cell Dysfunction and Exhaustion in Cancer. Front. Cell Dev. Biol. 2020;8:17. doi: 10.3389/fcell.2020.00017.
    1. Fares C.M., Van Allen E.M., Drake C.G., Allison J.P., Hu-Lieskovan S. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients? Am. Soc. Clin. Oncol. Educ. B. 2019:147–164. doi: 10.1200/EDBK_240837.
    1. Thommen D.S., Schumacher T.N. T Cell Dysfunction in Cancer. Cancer Cell. 2018;33:547–562. doi: 10.1016/j.ccell.2018.03.012.
    1. Jiang Y., Li Y., Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015;6:e1792. doi: 10.1038/cddis.2015.162.
    1. Philip M., Fairchild L., Sun L., Horste E.L., Camara S., Shakiba M., Scott A.C., Viale A., Lauer P., Merghoub T., et al. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature. 2017;545:452–456. doi: 10.1038/nature22367.
    1. Cai M., Zhao X., Cao M., Ma P., Chen M., Wu J., Jia C., He C., Fu Y., Tan L., et al. T-cell exhaustion interrelates with immune cytolytic activity to shape the inflamed tumor microenvironment. J. Pathol. 2020;251:147–159. doi: 10.1002/path.5435.
    1. Peng W., Chen J.Q., Liu C., Malu S., Creasy C., Tetzlaff M.T., Xu C., McKenzie J.A., Zhang C., Liang X., et al. Loss of PTEN promotes resistance to T cell–mediated immunotherapy. Cancer Discov. 2016;6:202–216. doi: 10.1158/-15-0283.
    1. Amodio N., Scrima M., Palaia L., Salman A.N., Quintiero A., Franco R., Botti G., Pirozzi P., Rocco G., De Rosa N., et al. Oncogenic role of the E3 ubiquitin ligase NEDD4-1, a PTEN negative regulator, in non-small-cell lung carcinomas. Am. J. Pathol. 2010;177:2622–2634. doi: 10.2353/ajpath.2010.091075.
    1. Soria J.-C., Lee H.-Y., Lee J.I., Wang L., Issa J.-P., Kemp B.L., Liu D.D., Kurie J.M., Mao L., Khuri F.R. Lack of PTEN Expression in Non-Small Cell Lung Cancer Could Be Related to Promoter Methylation. Clin. Cancer Res. 2002;8:1178–1184.
    1. Marsit C.J., Zheng S., Aldape K., Hinds P.W., Nelson H.H., Wiencke J.K., Kelsey K.T. PTEN expression in non-small-cell lung cancer: Evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum. Pathol. 2005;36:768–776. doi: 10.1016/j.humpath.2005.05.006.
    1. Spranger S., Bao R., Gajewski T.F. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature. 2015;523:231–235. doi: 10.1038/nature14404.
    1. Spranger S., Gajewski T. Rational combinations of immunotherapeutics that target discrete pathways. J. Immunother. Cancer. 2013;1:16. doi: 10.1186/2051-1426-1-16.
    1. Zaretsky J.M., Garcia-Diaz A., Shin D.S., Escuin-Ordinas H., Hugo W., Hu-Lieskovan S., Torrejon D.Y., Abril-Rodriguez G., Sandoval S., Barthly L., et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 2016;375:819–829. doi: 10.1056/NEJMoa1604958.
    1. Kitajima S., Ivanova E., Guo S., Yoshida R., Campisi M., Sundararaman S.K., Tange S., Mitsuishi Y., Thai T.C., Masuda S., et al. Suppression of STING associated with lkb1 loss in KRAS-driven lung cancer. Cancer Discov. 2019;9:34–45. doi: 10.1158/-18-0689.
    1. Lagos G.G., Izar B., Rizvi N.A. Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor Immunotherapy. Am. Soc. Clin. Oncol. Educ. B. 2020;40:e47–e57. doi: 10.1200/EDBK_289967.
    1. Liu C., Peng W., Xu C., Lou Y., Zhang M., Wargo J.A., Chen J.Q., Li H.S., Watowich S.S., Yang Y., et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin. Cancer Res. 2013;19:393–403. doi: 10.1158/1078-0432.CCR-12-1626.
    1. Frisone D., Friedlaender A., Malapelle U., Banna G., Addeo A. A BRAF new world. Crit. Rev. Oncol. Hematol. 2020;152:103008. doi: 10.1016/j.critrevonc.2020.103008.
    1. Routy B., Le Chatelier E., Derosa L., Duong C.P.M., Alou M.T., Daillère R., Fluckiger A., Messaoudene M., Rauber C., Roberti M.P., et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91–97. doi: 10.1126/science.aan3706.
    1. Atarashi K., Tanoue T., Shima T., Imaoka A., Kuwahara T., Momose Y., Cheng G., Yamasaki S., Saito T., Ohba Y., et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science. 2011;331:337–341. doi: 10.1126/science.1198469.
    1. Gaboriau-Routhiau V., Rakotobe S., Lécuyer E., Mulder I., Lan A., Bridonneau C., Rochet V., Pisi A., De Paepe M., Brandi G., et al. The Key Role of Segmented Filamentous Bacteria in the Coordinated Maturation of Gut Helper T Cell Responses. Immunity. 2009;31:677–689. doi: 10.1016/j.immuni.2009.08.020.
    1. Mazmanian S.K., Cui H.L., Tzianabos A.O., Kasper D.L. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell. 2005;122:107–118. doi: 10.1016/j.cell.2005.05.007.
    1. Tanoue T., Morita S., Plichta D.R., Skelly A.N., Suda W., Sugiura Y., Narushima S., Vlamakis H., Motoo I., Sugita K., et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature. 2019;565:600–605. doi: 10.1038/s41586-019-0878-z.
    1. Adachi K., Tamada K. Microbial biomarkers for immune checkpoint blockade therapy against cancer. J. Gastroenterol. 2018;53:999–1005. doi: 10.1007/s00535-018-1492-9.
    1. Chen P.L., Roh W., Reuben A., Cooper Z.A., Spencer C.N., Prieto P.A., Miller J.P., Bassett R.L., Gopalakrishnan V., Wani K., et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 2016;6:827–837. doi: 10.1158/-15-1545.
    1. Shien K., Papadimitrakopoulou V.A., Wistuba I.I. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non–small cell lung cancer. Lung Cancer. 2016;99:79–87. doi: 10.1016/j.lungcan.2016.06.016.
    1. Paz-Ares L., Dvorkin M., Chen Y., Reinmuth N., Hotta K., Trukhin D., Statsenko G., Hochmair M.J., Özgüroğlu M., Ji J.H., et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929–1939. doi: 10.1016/S0140-6736(19)32222-6.
    1. Lantuejoul S., Sound-Tsao M., Cooper W.A., Girard N., Hirsch F.R., Roden A.C., Lopez-Rios F., Jain D., Chou T.Y., Motoi N., et al. PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. J. Thorac. Oncol. 2020;15:499–519. doi: 10.1016/j.jtho.2019.12.107.
    1. Ishii H., Azuma K., Kawahara A., Yamada K., Imamura Y., Tokito T., Kinoshita T., Kage M., Hoshino T. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. J. Thorac. Oncol. 2015;10:426–430. doi: 10.1097/JTO.0000000000000414.
    1. Iams W.T., Porter J., Horn L. Immunotherapeutic approaches for small-cell lung cancer. Nat. Rev. Clin. Oncol. 2020;17:300–312. doi: 10.1038/s41571-019-0316-z.
    1. Bianco A., Perrotta F., Barra G., Malapelle U., Rocco D., De Palma R. Prognostic factors and biomarkers of responses to immune checkpoint inhibitors in lung cancer. Int. J. Mol. Sci. 2019;20:4931. doi: 10.3390/ijms20194931.
    1. Tumeh P.C., Harview C.L., Yearley J.H., Shintaku I.P., Taylor E.J.M., Robert L., Chmielowski B., Spasic M., Henry G., Ciobanu V., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–571. doi: 10.1038/nature13954.
    1. Maia M.C., Almeida L., Bergerot P.G., Dizman N., Pal S.K. Relationship of tumor mutational burden (TMB) to immunotherapy response in metastatic renal cell carcinoma (mRCC) J. Clin. Oncol. 2018;36:662. doi: 10.1200/JCO.2018.36.6_suppl.662.
    1. Wu Y., Xu J., Xu J., Wang Y., Wang L., Lv W., Hu J. The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age. Biomark. Res. 2020;8:1–5. doi: 10.1186/s40364-020-00188-2.
    1. Ricciuti B., Kravets S., Dahlberg S.E., Umeton R., Albayrak A., Subegdjo S.J., Johnson B.E., Nishino M., Sholl L.M., Awad M.M. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer. J. Immunother. Cancer. 2019;7:87. doi: 10.1186/s40425-019-0572-6.
    1. Botticelli A., Cerbelli B., Lionetto L., Zizzari I., Salati M., Pisano A., Federica M., Simmaco M., Nuti M., Marchetti P. Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC? J. Transl. Med. 2018;16:1–6. doi: 10.1186/s12967-018-1595-3.
    1. Papillon-Cavanagh S., Doshi P., Dobrin R., Szustakowski J., Walsh A.M. STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort. ESMO Open. 2020;5:e000706. doi: 10.1136/esmoopen-2020-000706.
    1. Pérez-Callejo D., Romero A., Provencio M., Torrente M. Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring. Transl. Lung Cancer Res. 2016;5:455–465. doi: 10.21037/tlcr.2016.10.07.
    1. Ornatsky O., Bandura D., Baranov V., Nitz M., Winnik M.A., Tanner S. Highly multiparametric analysis by mass cytometry. J. Immunol. Methods. 2010;361:1–20. doi: 10.1016/j.jim.2010.07.002.
    1. Arora S., Velichinskii R., Lesh R.W., Ali U., Kubiak M., Bansal P., Borghaei H., Edelman M.J., Boumber Y. Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors. Adv. Ther. 2019;36:2638–2678. doi: 10.1007/s12325-019-01051-z.
    1. Anagnostou V., Forde P.M., White J.R., Niknafs N., Hruban C., Naidoo J., Marrone K., Ashok Sivakumar I.K., Bruhm D.C., Rosner S., et al. Dynamics of tumor and immune responses during immune checkpoint blockade in non–small cell lung cancer. Cancer Res. 2019;79:1214–1225. doi: 10.1158/0008-5472.CAN-18-1127.
    1. Li C., Li C., Zhi C., Liang W., Wang X., Chen X., Lv T., Shen Q., Song Y., Lin D., et al. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients. J. Transl. Med. 2019;17:355. doi: 10.1186/s12967-019-2101-2.
    1. Pasini L., Ulivi P. Extracellular vesicles in non-small-cell lung cancer: Functional role and involvement in resistance to targeted treatment and immunotherapy. Cancers. 2019;12:40. doi: 10.3390/cancers12010040.
    1. Hirsch F.R., McElhinny A., Stanforth D., Ranger-Moore J., Jansson M., Kulangara K., Richardson W., Towne P., Hanks D., Vennapusa B., et al. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J. Thorac. Oncol. 2017;12:208–222. doi: 10.1016/j.jtho.2016.11.2228.
    1. Wu H.J., Wu E. The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes. 2012;3:4–14. doi: 10.4161/gmic.19320.
    1. Belkaid Y., Hand T.W. Role of the microbiota in immunity and inflammation. Cell. 2014;157:121–141. doi: 10.1016/j.cell.2014.03.011.
    1. Kim D., Yoo S.A., Kim W.U. Gut microbiota in autoimmunity: Potential for clinical applications. Arch. Pharm. Res. 2016;39:1565–1576. doi: 10.1007/s12272-016-0796-7.
    1. Gong J., Chehrazi-Raffle A., Placencio-Hickok V., Guan M., Hendifar A., Salgia R. The gut microbiome and response to immune checkpoint inhibitors: Preclinical and clinical strategies. Clin. Transl. Med. 2019;8:9. doi: 10.1186/s40169-019-0225-x.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner